First human test of Triple-Threat vaccine targets common respiratory viruses
NCT ID NCT07295028
Summary
This early-stage study is testing a new combined vaccine designed to protect older adults against three common viruses that cause respiratory infections: RSV, hMPV, and PIV3. Researchers will give 240 healthy participants aged 60-83 either the experimental vaccine, comparison vaccines, or a placebo shot to check safety and how well it triggers immune responses. This is the first time all three components are being tested together in people.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emeritus Research
NOT_YET_RECRUITINGCamberwell, Australia
Contact
-
Momentum Clinical Research
NOT_YET_RECRUITINGDarlinghurst, Australia
Contact
-
University of Sunshine Coast, South Bank
RECRUITINGBrisbane, Australia
Contact
-
University of the Sunshine Coast
NOT_YET_RECRUITINGMorayfield, Australia
Contact
-
University of the Sunshine Coast, Sippy Downs
NOT_YET_RECRUITINGSippy Downs, Australia
Contact
-
Veritus Research
NOT_YET_RECRUITINGMelbourne, Australia
Contact
Conditions
Explore the condition pages connected to this study.